Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 15/20 | 1.00 |
| ▸ | GLRB | P48167 | 15/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.79 |
| ▸ | SCN1A | P35498 | 1/20 | 0.79 |
| ▸ | TAS2R46 | P59540 | 1/20 | 0.79 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.79 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24177883 | 1.00 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL12549549 | 0.88 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL93798 | 0.88 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL5317062 | 0.87 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL25300604 | 0.87 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| SCHEMBL23694422 | 0.86 | TAS2R10 (0.79) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| SCHEMBL23693967 | 0.86 | TAS2R10 (0.79) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| SCHEMBL23693968 | 0.86 | TAS2R10 (0.79) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL578374 | 0.85 | GLRA1 (0.93) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Brucine SCHEMBL113229 | 0.84 | TAS2R10 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682152-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CNS RESPONSE (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1682152-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CNS Response (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050118286-A1 | Compositions and methods for treatment of nervous system disorders | CNS RESPONSE | 2005-06-02 | — | — | US | disclosed |
| WO-2005044190-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CNS RESPONSE (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050096311-A1 | comprising an anticonvulsant and a neuroactive modulator; eg childhood disorders, cognitive disorders, substance disorders, schizophrenia, psychotic disorders mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, sexual disorders, gender identity disorders | CNS RESPONSE (US) | 2005-05-05 | — | — | US | disclosed |